Topical Fibrosis Formulation for Non-Invasive Plaque Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Peyronie's disease, Dupuytren's contracture, Ledderhose Fibrosis, and related connective tissue disorders are largely ineffective, invasive, or associated with significant side effects, necessitating a need for a tolerable, effective, and convenient therapeutic option.
Innovation Solution
Topical compositions containing calcium channel blockers, superoxide dismutase, and emu oil, optionally with penetration enhancers, are applied to treat sub-dermal plaque accumulations and scar tissue, providing a non-invasive approach to reduce symptoms and severity of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgery is performed to treat Peyronie's disease, then predictable efficacy is achieved, but complications and patient discomfort increase
Solution Approach 1:
The patent replaces surgical mechanical intervention with a topical chemical formulation. The composition uses calcium channel blockers, superoxide dismutase, and emu oil to chemically modify and reduce plaque tissue, substituting the mechanical cutting and manipulation of surgery with a non-invasive chemical treatment that achieves similar therapeutic effects without surgical complications
Solution Approach 2:
The patent introduces a topical composition as an intermediary substance between the patient's condition and the desired therapeutic outcome. This formulation acts as a mediator that delivers active ingredients directly to the affected tissue, providing predictable efficacy through a controlled chemical mechanism rather than direct surgical intervention
2Reliability
If intra-lesional injections are administered, then some treatment effect is achieved, but treatment complexity and patient discomfort increase
Solution Approach 1:
The patent extracts the active therapeutic ingredients from the complex injection procedure and delivers them through a simple topical formulation. By removing the need for needle injection and using a topical application instead, the treatment maintains its therapeutic effect while dramatically improving ease of operation and patient convenience
Solution Approach 2:
The patent changes the administration parameter from injection (intra-lesional) to topical application. This parameter change transforms a complex, invasive procedure into a simple, non-invasive treatment that is easier to administer and more convenient for patients while maintaining treatment effectiveness
3Reliability
If laser technology is used to reduce plaques, then some efficacy is achieved, but treatment cost and accessibility increase
Solution Approach 1:
The patent replaces expensive, specialized laser equipment with an inexpensive topical formulation that can be manufactured and distributed widely. The topical composition serves as a low-cost alternative to high-tech laser treatment, making effective plaque reduction therapy accessible to a broader patient population without requiring expensive medical equipment
Solution Approach 2:
The patent substitutes complex laser technology with a simple topical chemical formulation. By replacing the sophisticated mechanical/optical laser system with a straightforward topical application, the treatment achieves plaque reduction effectiveness while dramatically improving ease of manufacture and accessibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively alleviate pain, improve penile flexibility, and reduce sexual dysfunction by targeting fibrotic tissue, offering higher success rates and patient comfort compared to existing therapies.
Implementation Method 1
The composition can include one or more non-invasive transdermal carrier agents
Implementation Method 2
The composition can include one or more penetration enhancers
Data Source
AI summary
The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.